RESUMO
Vascular endothelial cells are covered with glycocalyx comprising heparan sulfate, hyaluronan, chondroitin sulfate, and associated proteins. Glomerular endothelial glycocalyx is involved in protecting against induction of proteinuria and structural damage, but the specific components in glycocalyx that represent therapeutic targets remain unclear. Anti-vascular endothelial growth factor (VEGF) therapy is associated with an increased risk of glomerular endothelial injury. This study investigated whether hyaluronan could provide a therapeutic target to protect against proteinuria. We conducted ex vivo and in vivo experiments to explore the effects of degrading glomerular hyaluronan by administering hyaluronidase and of supplementation with hyaluronan. We investigated hyaluronan expression using biotin-labeled hyaluronan-binding protein (HABP) in human kidney specimens or serum hyaluronan in endothelial injuries under inhibition of VEGF signaling. We directly demonstrated hyaluronan in glomerular endothelial layers using HABP staining. Ex vivo and in vivo experiments showed the development of proteinuria after digestion of hyaluronan in glomerular capillaries. Supplementation with hyaluronan after hyaluronidase treatment suppressed proteinuria. Mice in the in vivo study developed albuminuria after intraperitoneal injection of hyaluronidase with decreased glomerular hyaluronan and increased serum hyaluronan. In human kidneys with endothelial cell dysfunction and proteinuria due to inhibition of VEGF, glomerular expression of hyaluronan was reduced even in normal-appearing glomeruli. Serum hyaluronan levels were elevated in patients with pre-eclampsia with VEGF signaling inhibition. Our data suggest that hyaluronan itself plays crucial roles in preventing proteinuria and preserving the integrity of endothelial cells. Hyaluronan could provide a therapeutic target for preventing glomerular endothelial glycocalyx damage, including VEGF signaling inhibition.
Assuntos
Células Endoteliais/metabolismo , Glicocálix/metabolismo , Ácido Hialurônico/biossíntese , Glomérulos Renais/metabolismo , Proteinúria/metabolismo , Animais , Bovinos , Células Endoteliais/efeitos dos fármacos , Células Endoteliais/patologia , Feminino , Glicocálix/efeitos dos fármacos , Glicocálix/patologia , Humanos , Hialuronoglucosaminidase/administração & dosagem , Glomérulos Renais/efeitos dos fármacos , Glomérulos Renais/patologia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Técnicas de Cultura de Órgãos , Gravidez , Proteinúria/patologia , Ratos , Ratos Endogâmicos LewRESUMO
BACKGROUND: Few studies have demonstrated the suppressive effects of amino acids (AAs) on the level of cortisol during exercise in humans. We hypothesized that an AA mixture containing arginine, which promotes lipid metabolism, valine, which effectively decreases the level of glucocorticoid, and serine, a substrate in the production of phosphatidylserine that is reported to blunt increases in cortisol, would suppress the exercise-induced cortisol response by combining the positive effects of the AAs synergistically. METHODS: A randomized, double-blinded, placebo-controlled crossover trial was conducted. Twenty healthy recreationally active males ingested either an AA mixture containing 1.8 g of arginine, 1.1 g of valine, and 0.1 g of serine or a placebo. Thirty minutes after ingestion, subjects performed an exercise trial on a cycle ergometer for 80 min at 50% maximal oxygen consumption. Plasma cortisol and other blood parameters immediately before and after the exercise were evaluated. RESULTS: Plasma cortisol concentrations after exercise were significantly higher than those before exercise in the placebo condition (9.51 ± 0.85 vs 14.39 ± 2.15, p < 0.05), while there was no significant difference in the AA condition (9.71 ± 0.93 vs 9.99 ± 1.23, p = 0.846). In addition, the increase in plasma cortisol before and after exercise was significantly lower in the AA condition than in the placebo condition (0.28 [- 2.75, 3.31] vs 4.87 [0.89, 8.86], p < 0.05). For the level of adrenocorticotropin, there was a significant difference between before and after exercise only in the placebo condition (24.21 ± 2.91 vs 53.17 ± 6.97, p < 0.01) but not in the AA condition (27.33 ± 3.60 vs 46.92 ± 10.41, p = 0.057). Blood glucose, plasma lactate, plasma ammonia, serum creatine phosphokinase, serum total ketone body, and serum free fatty acid were also significantly changed by the exercise load in both conditions, but no significant differences were observed between the two conditions. CONCLUSIONS: The present study demonstrated that the AA mixture suppressed the cortisol response during exercise without affecting exercise-related biological parameters such as glucose or lipid metabolism. TRIAL REGISTRATION: UMIN Clinical Trials Registry, UMIN000023587 . Registered 19 August 2016.
Assuntos
Arginina/administração & dosagem , Suplementos Nutricionais , Exercício Físico , Hidrocortisona/sangue , Serina/administração & dosagem , Valina/administração & dosagem , Adulto , Cápsulas , Estudos Cross-Over , Método Duplo-Cego , Voluntários Saudáveis , Humanos , MasculinoRESUMO
We tested the hypothesis that α-lactalbumin inhibits the disruption of intestinal barrier function and liver cirrhosis by restoring gut-liver axis function in thioacetamide (TAA) -treated rats. Rat diets were supplemented with α-lactalbumin replacing 50% of dietary protein. After consuming α-lactalbumin for one week, rats were intraperitoneally injected with TAA twice a week for 14 weeks. The α-lactalbumin-enriched diet significantly inhibited the elevation of plasma alanine aminotransferase, aspartate aminotransferase, and hyaluronic acids. The supplement significantly reduced plasma lipopolysaccharide levels and increased occludin mRNA level. Hepatic fibrosis and regenerative nodules was developed and intestinal villi were shortened by TAA; α-Lactalbumin attenuated these histopathological changes. These results indicated that α-lactalbumin improved intestinal barrier function, suppressing endotoxin levels. These data also suggested that α-lactalbumin ameliorated the impairment of the gut-liver axis by TAA, inhibiting the development of liver cirrhosis.
Assuntos
Suplementos Nutricionais , Trato Gastrointestinal/efeitos dos fármacos , Lactalbumina/uso terapêutico , Cirrose Hepática Experimental/induzido quimicamente , Cirrose Hepática Experimental/dietoterapia , Fígado/efeitos dos fármacos , Substâncias Protetoras/uso terapêutico , Tioacetamida/farmacologia , Alanina Transaminase/sangue , Animais , Aspartato Aminotransferases/sangue , Fibrose/tratamento farmacológico , Trato Gastrointestinal/metabolismo , Expressão Gênica/efeitos dos fármacos , Ácido Hialurônico/sangue , Injeções Intraperitoneais , Lipopolissacarídeos/sangue , Fígado/metabolismo , Fígado/patologia , Cirrose Hepática Experimental/prevenção & controle , Masculino , RNA Mensageiro/genética , Ratos , Ratos Sprague-Dawley , Tioacetamida/administração & dosagem , Proteínas de Junções Íntimas/genéticaRESUMO
Although several kinds of amino acids (AAs) are known to affect physiological actions during exercise, little is known about the combined effects of a mixture of several AAs on fatigue during exercise. The aim of the present study was to investigate the effect of an AA mixture supplement containing arginine, valine, and serine on exercise-induced fatigue in healthy volunteers. These AAs were selected because they were expected to reduce fatigue during exercise by acting the positive effects synergistically. A randomized, double-blinded, placebo-controlled crossover trial was conducted. Thirty-nine males ingested an AA mixture containing 3600 mg of arginine, 2200 mg of valine, and 200 mg of serine or a placebo each day for 14 days. On the 14th day, the participants completed an exercise trial on a cycle ergometer at 50% of VO2max for 120 min. After the two-week washout period, the participants repeated the same trial with the other test sample. The participant's feeling of fatigue based on a visual analog scale (VAS) and a rating of perceived exertion (RPE), as well as blood and physical parameters were evaluated. The feeling of fatigue based on VAS and RPE were significantly improved in AA compared to those in placebo. In the blood analysis, the increase in serum total ketone bodies during exercise and plasma tryptophan/branched-chain amino acids were significantly lower in AA than those in placebo. The present study demonstrated that supplementation with an AA mixture containing arginine, valine, and serine reduced the feeling of fatigue during exercise. The AA mixture also changed several blood parameters, which may contribute to the anti-fatigue effect.
Assuntos
Arginina/administração & dosagem , Exercício Físico/fisiologia , Fadiga/prevenção & controle , Serina/administração & dosagem , Valina/administração & dosagem , Adulto , Arginina/farmacologia , Estudos Cross-Over , Método Duplo-Cego , Combinação de Medicamentos , Sinergismo Farmacológico , Fadiga/etiologia , Voluntários Saudáveis , Humanos , Masculino , Pessoa de Meia-Idade , Serina/farmacologia , Valina/farmacologiaRESUMO
BACKGROUND: When combined with exercise, dietary amino acid (AA) supplementation is an effective method for accelerating fat mobilization. However, the effects of single AAs combined with exercise on fat oxidation remains unclear. We hypothesized that consumption of a specific amino acid, L- phenylalanine, may result in the secretion of glucagon, and when combined with exercise may promote fat oxidation. METHODS: Six healthy, active male volunteers were randomized in a crossover study to ingest either phenylalanine (3 g/dose) or placebo. Thirty minutes after ingestion each subject performed workload trials on a cycle ergometer for 1 h at 50% of maximal oxygen consumption. RESULTS: Oral intake of phenylalanine caused a significant increase in the concentrations of plasma glycerol and glucagon during exercise. The respiratory exchange ratio was also decreased significantly following ingestion of phenylalanine. CONCLUSION: These results suggested that pre-exercise supplementation of phenylalanine may stimulate whole body fat oxidation. No serious or study-related adverse events were observed. TRIAL REGISTRATION: UMIN000027502 Registered 26 May 2017. Restrospectively registered.
Assuntos
Tecido Adiposo/efeitos dos fármacos , Tecido Adiposo/metabolismo , Exercício Físico/fisiologia , Metabolismo dos Lipídeos/efeitos dos fármacos , Fenilalanina/farmacologia , Adulto , Estudos Cross-Over , Suplementos Nutricionais , Método Duplo-Cego , Glucagon/sangue , Glicerol/sangue , Voluntários Saudáveis , Humanos , Masculino , Oxirredução/efeitos dos fármacos , Consumo de Oxigênio/efeitos dos fármacos , Fenômenos Fisiológicos da Nutrição Esportiva , Adulto JovemRESUMO
Although there have been many investigations of the beneficial effects of both exercise and amino acids (AAs), little is known about their combined effects on the single-dose ingestion of AAs for lipid metabolism during exercise. We hypothesize that taking a specific combination of AAs implicated in glucagon secretion during exercise may increase fat metabolism. We recently developed a new mixture, d-AA mixture (D-mix), that contains arginine, alanine, and phenylalanine to investigate fat oxidation. In a double-blind, placebo-controlled crossover study, 10 healthy male volunteers were randomized to ingest either D-mix (3 g/dose) or placebo. Subjects in each condition subsequently performed a physical task that included workload trials on a cycle ergometer at 50% of maximal oxygen consumption for 1 hr. After oral intake of D-mix, maximum serum concentrations of glycerol (9.32 ± 6.29 mg/L and 5.22 ± 2.22 mg/L, respectively; p = .028), free fatty acid level (0.77 ± 0.26 mEq/L and 0.63 ± 0.28 mEq/L, respectively; p = .022), and acetoacetic acid levels (37.9 ± 17.7 µmol/L and 30.3 ± 13.9 µmol/L, respectively; p = .040) were significantly higher than in the placebo groups. The area under the curve for glucagon during recovery was numerically higher than placebo (6.61 ± 1.33 µg/L · min and 6.06 ± 1.23 µg/L · min, respectively; p = .099). These results suggest that preexercise ingestion of D-mix may stimulate fat metabolism. Combined with exercise, the administration of AA mixtures could prove to be a useful nutritional strategy to maximize fat metabolism.
Assuntos
Alanina/administração & dosagem , Arginina/administração & dosagem , Suplementos Nutricionais , Exercício Físico/fisiologia , Metabolismo dos Lipídeos/efeitos dos fármacos , Fenilalanina/administração & dosagem , Estudos Cross-Over , Método Duplo-Cego , Teste de Esforço , Humanos , Masculino , Consumo de Oxigênio , Fenômenos Fisiológicos da Nutrição Esportiva , Adulto JovemRESUMO
Cyclooxygenase-2 is expressed early in colon carcinogenesis and plays crucial role in the progress of the disease. Recently, we found that α-lactalbumin had anti-inflammatory activity by inhibiting cyclooxygenase-2. In experiment 1, we investigated the effects of α-lactalbumin on the colon carcinogenesis initiated with azoxymethane (AOM) followed by promotion with dextran sodium sulfate (DSS) in mice. Dietary treatment with α-lactalbumin decreased fecal occult blood score at 3 days after DSS intake. α-Lactalbumin also decreased the colon tumor at week 9. In experiment 2, AOM-treated mice were sacrificed at 7 days after DSS intake. The plasma and colon prostaglandin E2 (PGE2) levels in AOM/DSS-treated mice were higher than those in the DSS-treated mice without initiation by AOM. α-Lactalbumin decreased PGE2 in both plasma and colon. These results suggest that α-lactalbumin effectively inhibited colon carcinogenesis, and the inhibition may be due to the decreased PGE2 by inhibiting cyclooxygenase-2 at cancer promotion stages.
Assuntos
Anti-Inflamatórios não Esteroides/farmacologia , Azoximetano/farmacologia , Carcinogênese/efeitos dos fármacos , Colo/efeitos dos fármacos , Sulfato de Dextrana/farmacologia , Lactalbumina/farmacologia , Leite/química , Adenocarcinoma/induzido quimicamente , Adenocarcinoma/patologia , Adenocarcinoma/prevenção & controle , Adenoma/induzido quimicamente , Adenoma/patologia , Adenoma/prevenção & controle , Animais , Anti-Inflamatórios não Esteroides/uso terapêutico , Carcinogênese/induzido quimicamente , Bovinos , Colo/metabolismo , Colo/patologia , Neoplasias do Colo/induzido quimicamente , Neoplasias do Colo/patologia , Neoplasias do Colo/prevenção & controle , Suplementos Nutricionais , Dinoprostona/sangue , Dinoprostona/metabolismo , Inflamação/sangue , Inflamação/tratamento farmacológico , Inflamação/metabolismo , Inflamação/patologia , Interleucina-1beta/metabolismo , Lactalbumina/uso terapêutico , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Sangue Oculto , Tamanho do Órgão/efeitos dos fármacos , Fator de Necrose Tumoral alfa/metabolismoRESUMO
Milk whey proteins contain major components of alpha-lactalbumin (alphaLA) and beta-lactoglobulin (betaLG), and a minor component of lactoferrin (LF). It has been reported that LF reduces nociception and inflammation in various animal models. However, the efficacy of alphaLA and betaLG has not been clarified. This study aimed to assess the efficacy of alphaLA and betaLG in various animal models such as acetic acid-induced writhing, carrageenan-induced paw inflammation, and adjuvant induced-arthritis. Orally administered alphaLA showed (i) inhibition of writhing induced by acetic acid in mice; (ii) suppression of nociception and inflammation in rat footpads caused by carrageenan in rat; and (iii) therapeutic effects on the development of adjuvant-induced pain and inflammation in rat. In contrast, betaLG had no effects in these animal models. To clarify the anti-nociceptive and anti-inflammatory mechanisms of alphaLA, we examined the levels of interleukin (IL)-6 and prostaglandin (PG)E(2) in carrageenan-injected paw exudates. The administration of alphaLA 1 h before carrageenan injection inhibited the increased formation of IL-6 and PGE(2) in paw exudates. Next, we demonstrated in vitro enzyme-inhibition assay; cyclooxygenase (COX), phospholipase A(2), and 5-lipoxygenase. alphaLA inhibited COX and phospholipase A(2) activities. alphaLA inhibited COX and phospholipase A(2) activities. Moreover, alphaLA showed selectivity on COX-2 as compared with COX-1. However, 5-lipoxygenase activity was not affected by alphaLA. These results suggest that alphaLA is a safe and useful natural drug for patients that require anti-inflammatory drugs, as alphaLA is contained in dairy food and is frequently ingested as daily food.